MCID: ANL017
MIFTS: 48

Anal Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 15 73
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 50 C9161

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and in situ carcinoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Human cytomegalovirus infection and PI3K-Akt signaling pathway. The drugs Immunologic Factors and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.2 AKT1 CDKN2A PIK3CA TP53
2 in situ carcinoma 30.3 CDKN2A TP53
3 suppressor of tumorigenicity 3 30.2 CDKN2A TP53
4 cervix carcinoma 30.1 CDKN2A TP53
5 adenocarcinoma 29.2 AKT1 APC CDKN2A MLH1 PIK3CA TP53
6 papilloma 10.2
7 bladder squamous cell carcinoma 10.2 CDKN2A TP53
8 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
9 spitz nevus 10.2 CDKN2A TP53
10 bladder carcinoma in situ 10.2 CDKN2A TP53
11 vulva squamous cell carcinoma 10.2 CDKN2A TP53
12 scrotal carcinoma 10.2 CDKN2A TP53
13 vulvar disease 10.2 CDKN2A TP53
14 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
15 bartholin's gland disease 10.2 CDKN2A TP53
16 megaesophagus 10.2 CDKN2A TP53
17 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
18 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
19 anogenital venereal wart 10.2 CDKN2A TP53
20 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
21 uterus carcinoma in situ 10.2 CDKN2A TP53
22 oral leukoplakia 10.2 CDKN2A TP53
23 meningeal melanomatosis 10.2 CDKN2A TP53
24 dedifferentiated liposarcoma 10.2 CDKN2A TP53
25 endocervical adenocarcinoma 10.2 CDKN2A TP53
26 hyperplastic polyposis syndrome 10.2 APC TP53
27 penile disease 10.2 CDKN2A TP53
28 mutyh-associated polyposis 10.2 APC TP53
29 cervix small cell carcinoma 10.2 CDKN2A TP53
30 necrotizing sialometaplasia 10.2 CDKN2A TP53
31 verrucous carcinoma 10.2 CDKN2A TP53
32 basaloid squamous cell carcinoma 10.2 CDKN2A TP53
33 tongue disease 10.2 CDKN2A TP53
34 biliary tract neoplasm 10.2 CDKN2A TP53
35 optic nerve neoplasm 10.2 CDKN2A TP53
36 juvenile pilocytic astrocytoma 10.2 CDKN2A TP53
37 tonsil cancer 10.2 CDKN2A TP53
38 pre-malignant neoplasm 10.2 CDKN2A TP53
39 polyposis syndrome, hereditary mixed, 1 10.2 APC MLH1
40 recessive dystrophic epidermolysis bullosa 10.1 CDKN2A TP53
41 vulva cancer 10.1 CDKN2A TP53
42 adult hepatocellular carcinoma 10.1 PIK3CA TP53
43 squamous cell papilloma 10.1 CDKN2A TP53
44 malignant spiradenoma 10.1 PIK3CA TP53
45 laryngeal disease 10.1 CDKN2A TP53
46 breast squamous cell carcinoma 10.1 PIK3CA TP53
47 richter's syndrome 10.1 MLH1 TP53
48 thyroid lymphoma 10.1 TP53 TP73
49 barrett's adenocarcinoma 10.1 CDKN2A TP53
50 oropharynx cancer 10.1 CDKN2A TP53

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.12 FBXW7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.12 FBXW7
3 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.12 APC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.12 FBXW7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.12 FBXW7 PIK3CA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.12 AKT1 PIK3CA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.12 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.12 AKT1 APC FBXW7 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.12 FBXW7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.12 PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.12 APC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.12 APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.12 APC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.12 AKT1 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.12 FBXW7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.12 APC PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.12 AKT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.12 FBXW7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.12 AKT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.12 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.12 AKT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.12 AKT1
23 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.62 AKT1 CDKN2A MLH1 TP53 TP73
24 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.62 AKT1 CDKN2A MLH1 TP53 TP73
25 Decreased CDKN1A mRNA expression GR00389-S-1 9.33 FBXW7 TP53
26 Decreased CDKN1A mRNA expression GR00389-S-2 9.33 TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
2 endocrine/exocrine gland MP:0005379 10.15 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
3 cardiovascular system MP:0005385 10.13 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
4 homeostasis/metabolism MP:0005376 10.11 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
5 embryo MP:0005380 10.1 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
6 immune system MP:0005387 10.1 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
7 growth/size/body region MP:0005378 10.08 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
8 hematopoietic system MP:0005397 10.07 AKT1 APC CDKN2A FBXW7 MLH1 TP53
9 digestive/alimentary MP:0005381 10.04 APC CDKN2A FBXW7 MLH1 TP53 TP73
10 mortality/aging MP:0010768 10.03 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
11 integument MP:0010771 10.02 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
12 neoplasm MP:0002006 9.97 AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
13 nervous system MP:0003631 9.87 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
14 liver/biliary system MP:0005370 9.85 AKT1 APC CDKN2A FBXW7 TP53
15 muscle MP:0005369 9.8 AKT1 APC CDKN2A PIK3CA TP53
16 reproductive system MP:0005389 9.8 AKT1 APC CDKN2A MLH1 PIK3CA TP53
17 respiratory system MP:0005388 9.63 AKT1 CDKN2A FBXW7 MLH1 TP53 TP73
18 skeleton MP:0005390 9.43 AKT1 APC CDKN2A PIK3CA TP53 TP73
19 vision/eye MP:0005391 9.17 APC CDKN2A FBXW7 MLH1 PIK3CA TP53

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
5
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
6 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
10 Antimitotic Agents Phase 3,Phase 2
11 Albumin-Bound Paclitaxel Phase 3,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
13 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
14 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
15 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
16 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
17
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
18
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
19
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
20
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
23
Pembrolizumab Approved Phase 2 1374853-91-4
24 Antibodies, Monoclonal Phase 2,Phase 1
25 Antibodies Phase 2,Phase 1
26 Immunoglobulins Phase 2,Phase 1
27 Psychotropic Drugs Phase 2
28 GABA Agents Phase 2
29 Neurotransmitter Agents Phase 2
30 Tranquilizing Agents Phase 2
31 Anticonvulsants Phase 2
32 Antimanic Agents Phase 2
33 Central Nervous System Depressants Phase 2
34 taxane Phase 2
35
Cyclophosphamide Approved, Investigational Phase 1 6055-19-2, 50-18-0 2907
36
Nivolumab Approved Phase 1 946414-94-4
37
Fludarabine Approved Phase 1 75607-67-9, 21679-14-1 30751
38
Manganese Approved, Nutraceutical Phase 1 7439-96-5 27854
39 Vaccines Phase 1
40 Antineoplastic Agents, Alkylating Phase 1
41 Antirheumatic Agents Phase 1
42
Dimenhydrinate Approved 523-87-5 441281
43
Hydrogen peroxide Approved, Vet_approved 7722-84-1 784
44
Ethanol Approved 64-17-5 702
45 Pharmaceutical Solutions

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
3 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
4 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
5 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
6 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
8 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
9 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
10 Vectibix for the Treatment of Anal Cancer Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
11 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
12 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
13 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
14 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
15 A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
16 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
17 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
18 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
19 A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer Recruiting NCT02797964 Phase 1, Phase 2 SRA737
20 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Active, not recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
21 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
22 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
23 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
24 A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Withdrawn NCT02857608 Phase 2 Lymphoseek
25 A Phase 1 Study in Participants With Advanced Cancer Completed NCT01115790 Phase 1 Prexasertib
26 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
27 Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer Recruiting NCT03386500 Phase 1 BMX-001
28 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
29 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02408861 Phase 1
30 ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Completed NCT02145416
31 Molecular Biology of Anal Cancer in HIV-Positive Patients Completed NCT00952874
32 Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor? Completed NCT03469596
33 Anal Dysplasia in Patients With Inflammatory Bowel Disease Completed NCT01653054 Not Applicable
34 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
35 Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients Recruiting NCT01877135
36 Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) Recruiting NCT03241680 Not Applicable
37 Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men Recruiting NCT02816879 Not Applicable
38 Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021 Not Applicable
39 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Active, not recruiting NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
40 Seville Cohort of People Living With HIV at Risk for Anal Cancer Enrolling by invitation NCT03713229
41 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Not yet recruiting NCT03061435 Not Applicable
42 Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Terminated NCT02407561
43 Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer Withdrawn NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

41
Cervix, Lung, Brain, Bone, Breast, Pancreas, Thyroid

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 110)
# Title Authors Year
1
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
2
Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )
2018
3
Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )
2018
4
Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ( 29514401 )
2018
5
Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )
2018
6
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )
2018
7
Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )
2018
8
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. ( 29466950 )
2018
9
ASO Author Reflections: The Role of Tumor Size in the Prognosis of Anal Squamous Cell Carcinoma: A Validation on the New American Joint Committee on Cancer Subclassification of Stage IIA and B. ( 30367300 )
2018
10
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. ( 30415990 )
2018
11
Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study. ( 30504412 )
2018
12
Multiple primary malignancies in patients with anal squamous cell carcinoma. ( 30505585 )
2018
13
Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )
2018
14
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )
2018
15
The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. ( 29487716 )
2018
16
Anal squamous cell carcinoma - State of the art management and future perspectives. ( 29494827 )
2018
17
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. ( 30042063 )
2018
18
Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. ( 30054279 )
2018
19
Oestrogen receptor can be expressed by normal and dysplastic anal squamous epithelia but only rarely by anal squamous cell carcinoma. ( 30062743 )
2018
20
Anal squamous cell carcinoma: are we improving outcomes? ( 30159994 )
2018
21
Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. ( 30194195 )
2018
22
Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )
2017
23
Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )
2017
24
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )
2017
25
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )
2017
26
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )
2017
27
High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )
2017
28
Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )
2017
29
Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )
2017
30
Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )
2017
31
Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )
2017
32
The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )
2017
33
Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )
2017
34
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )
2017
35
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )
2016
36
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )
2016
37
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )
2016
38
Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )
2016
39
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )
2016
40
Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )
2016
41
Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )
2016
42
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )
2016
43
Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )
2016
44
Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. ( 27852700 )
2016
45
Anal squamous cell carcinoma in chronic severe perianal Crohn's disease. ( 25702309 )
2015
46
Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the "bolus effect" of radiation therapy. ( 27051789 )
2015
47
A tumor control probability model for anal squamous cell carcinoma. ( 26243680 )
2015
48
Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. ( 26287957 )
2015
49
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. ( 25810165 )
2015
50
Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 24839133 )
2015

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 AKT1 CDKN2A PIK3CA TP53
2
Show member pathways
12.85 AKT1 APC PIK3CA TP53
3
Show member pathways
12.78 AKT1 CDKN2A MLH1 TP53 TP73
4
Show member pathways
12.65 AKT1 CDKN2A PIK3CA TP53 TP73
5
Show member pathways
12.64 AKT1 PIK3CA TP53 TP73
6
Show member pathways
12.61 AKT1 CDKN2A PIK3CA TP53
7
Show member pathways
12.59 AKT1 APC CDKN2A MLH1 PIK3CA TP53
8
Show member pathways
12.54 AKT1 APC PIK3CA TP53 TP73
9 12.52 AKT1 APC CDKN2A MLH1 PIK3CA TP53
10 12.38 APC CDKN2A PIK3CA TP53
11
Show member pathways
12.37 AKT1 PIK3CA TP53
12 12.36 CDKN2A MLH1 TP53 TP73
13
Show member pathways
12.35 AKT1 APC PIK3CA TP53
14
Show member pathways
12.34 AKT1 PIK3CA TP53
15
Show member pathways
12.33 AKT1 PIK3CA TP53
16 12.32 AKT1 APC TP53
17
Show member pathways
12.3 AKT1 APC CDKN2A MLH1 PIK3CA TP53
18
Show member pathways
12.29 AKT1 PIK3CA TP53
19
Show member pathways
12.27 CDKN2A TP53 TP73
20 12.25 APC CDKN2A TP53
21 12.24 AKT1 APC CDKN2A PIK3CA TP53
22
Show member pathways
12.21 AKT1 PIK3CA TP53
23 12.18 AKT1 PIK3CA TP53
24 12.17 AKT1 PIK3CA TP53
25 12.17 CDKN2A PIK3CA TP53
26
Show member pathways
12.1 AKT1 PIK3CA TP53
27
Show member pathways
12.05 AKT1 PIK3CA TP53
28 12.05 AKT1 APC MLH1 TP53
29 12.03 AKT1 CDKN2A PIK3CA TP53
30
Show member pathways
12.01 AKT1 PIK3CA TP53
31 12 AKT1 PIK3CA TP53
32 11.97 AKT1 PIK3CA TP53
33 11.97 AKT1 APC PIK3CA
34 11.94 AKT1 PIK3CA TP53
35 11.92 APC MLH1 TP53 TP73
36
Show member pathways
11.9 AKT1 TP53 TP73
37
Show member pathways
11.9 AKT1 PIK3CA TP53
38 11.87 AKT1 PIK3CA TP53
39 11.86 AKT1 PIK3CA TP53
40 11.8 AKT1 APC CDKN2A TP53
41 11.76 AKT1 PIK3CA TP53
42
Show member pathways
11.64 AKT1 CDKN2A TP53
43
Show member pathways
11.57 AKT1 PIK3CA TP53
44 11.56 AKT1 PIK3CA TP53
45 11.52 AKT1 FBXW7 PIK3CA TP53
46 11.45 AKT1 MLH1 TP53
47 11.39 AKT1 PIK3CA
48 11.38 AKT1 APC
49 11.38 AKT1 PIK3CA
50
Show member pathways
11.35 MLH1 TP53

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.7 AKT1 APC CDKN2A FBXW7 PIK3CA TP53
2 mitochondrion GO:0005739 9.35 AKT1 CDKN2A FBXW7 TP53 TP73
3 nucleoplasm GO:0005654 9.17 AKT1 APC CDKN2A FBXW7 MLH1 TP53

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.86 AKT1 CDKN2A TP53 TP73
2 cytokine-mediated signaling pathway GO:0019221 9.79 AKT1 PIK3CA TP53
3 cell cycle GO:0007049 9.78 CDKN2A MLH1 TP53 TP73
4 regulation of apoptotic process GO:0042981 9.77 AKT1 TP53 TP73
5 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 CDKN2A TP53 TP73
6 protein destabilization GO:0031648 9.62 CDKN2A FBXW7
7 negative regulation of Notch signaling pathway GO:0045746 9.61 AKT1 FBXW7
8 protein kinase B signaling GO:0043491 9.6 AKT1 PIK3CA
9 protein tetramerization GO:0051262 9.58 TP53 TP73
10 phosphatidylinositol 3-kinase signaling GO:0014065 9.58 AKT1 PIK3CA
11 mismatch repair GO:0006298 9.57 MLH1 TP73
12 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.55 TP53 TP73
13 cellular response to DNA damage stimulus GO:0006974 9.55 AKT1 APC MLH1 TP53 TP73
14 positive regulation of cell cycle arrest GO:0071158 9.54 TP53 TP73
15 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.52 APC CDKN2A
16 vasculature development GO:0001944 9.51 FBXW7 PIK3CA
17 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.49 TP53 TP73
18 apoptotic mitochondrial changes GO:0008637 9.43 AKT1 CDKN2A
19 regulation of signal transduction by p53 class mediator GO:1901796 9.43 AKT1 TP53 TP73
20 negative regulation of macroautophagy GO:0016242 9.4 AKT1 PIK3CA
21 replicative senescence GO:0090399 9.37 CDKN2A TP53
22 anoikis GO:0043276 9.32 AKT1 PIK3CA
23 cell cycle arrest GO:0007050 9.26 APC CDKN2A TP53 TP73
24 positive regulation of apoptotic process GO:0043065 9.02 AKT1 APC CDKN2A TP53 TP73

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.5 APC FBXW7 TP53
2 identical protein binding GO:0042802 9.35 AKT1 APC FBXW7 TP53 TP73
3 disordered domain specific binding GO:0097718 9.26 CDKN2A TP53
4 protein phosphatase 2A binding GO:0051721 9.16 AKT1 TP53
5 protein kinase binding GO:0019901 9.02 AKT1 APC CDKN2A TP53 TP73

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....